Director Dealings

RNS Number : 1314H

Oxford Biomedica PLC

01 December 2020

 

Director Dealings

Oxford, UK - 01 December 2020:   Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB   a leading gene and cell therapy group, today announces that Dr. Andrew Heath, a Non-Executive Director of the Group, sold 28,597 ordinary shares of 50p each ("Ordinary Shares") in the Company on 30 November 2020 on the London Stock Exchange at a price of 869.2p.

15,756 Ordinary Shares were sold by Dr. Heath's wife (Eva Lackner) on 30 November 2020 on the London Stock Exchange at a price of 868.8p and are therefore considered a beneficial holding of Dr. Heath.

Following these sales Dr. Andrew Heath holds 11,628 shares representing 0.01% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.	Details of the person discharging material responsibilities/person closely   associated
a.	Name	Dr. Andrew Heath
2.	Reason for the notification
a.	Position/status	Non-Executive Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Disposal of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£8.69	28,597
e.	Aggregated information · Aggregated volume · Price · Aggregated total	28,597  8.6922  248,570.84
f.	Date of the transaction	2020-11-30
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely   associated
a.	Name	Eva Lackner
2.	Reason for the notification
a.	Position/status	Person closely associated with Dr. Andrew Heath, Non- Executive Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Disposal of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£8.69	15,756
e.	Aggregated information · Aggregated volume · Price · Aggregated total	15,756  8.6883  136,892.85
f.	Date of the transaction	2020-11-30
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Group is 82,294,468 ordinary 50p shares.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at  www.oxb.com

 

END

 

 

DSHMZMGZZMFGGZM